Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …

Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the
world's population show serological evidence of current or past infection. Hepatitis B virus is …

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. There is
uncertainty around the economic burden of NAFLD. We constructed a steady‐state …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …

Chronic hepatitis B viral (HBV) infection remains a significant global health problem.
Evidence‐based guidelines are needed to help providers determine when treatment should …

Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …

Background Tenofovir alafenamide is a novel prodrug formulated to deliver the active
metabolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose …

This article has an accompanying continuing medical education activity on page e16.
Learning Objective: Upon completion of the CME activity, successful learners will be able to …

In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus
(HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently …